Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Unclassifiable Progressive Fibrosing ILD
NCT03099187Phase 2Completed
- Sponsor
- Roche
- Start
- May 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of pirfenidone in unclassifiable progressive fibrosing interstitial lung disease, sponsored by Roche. Started May 2017; status: completed.
02
Drugs
pirfenidone
03
Conditions
unclassifiable progressive fibrosing interstitial lung disease
Beyond the preview
Go deeper on NCT03099187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099187.